BlackRock Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

BlackRock Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$56.9M	Buy	521,832 +11,773	+2%	+$1.31M	0.03%	571
2016 Q3	$62M	Sell	510,059 -7,852	-2%	-$1.06M	0.03%	540
2016 Q2	$73.2M	Sell	517,911 -8,454	-2%	-$1.25M	0.04%	492
2016 Q1	$68.7M	Buy	526,365 +15,324	+3%	+$1.91M	0.04%	494
2015 Q4	$71.8M	Buy	511,041 +95,753	+23%	+$13.3M	0.04%	477
2015 Q3	$55.2M	Buy	415,288 +19,180	+5%	+$3.3M	0.03%	533
2015 Q2	$69.7M	Buy	+396,108	New	+$71.1M	0.04%	492
2015 Q1	–	Sell	-337,458	Closed	-$55.3M	–	2866
2014 Q4	$55.3M	Buy	337,458 +175,527	+108%	+$29.1M	0.03%	560
2014 Q3	$26M	Buy	161,931 +131,629	+434%	+$20.2M	0.02%	724
2014 Q2	$4.46M	Sell	30,302 -14,483	-32%	-$2.01M	﹤0.01%	1148
2014 Q1	$6.21M	Buy	44,785 +11,458	+34%	+$1.72M	﹤0.01%	1051
2013 Q4	$4.22M	Buy	33,327 +4,962	+17%	+$513K	﹤0.01%	1130
2013 Q3	$2.61M	Buy	28,365 +4,621	+19%	+$373K	﹤0.01%	1328
2013 Q2	$1.63M	Buy	+23,744	New	+$1.45M	﹤0.01%	1392

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's JAZZ Position: Q4 2016 in Review

BlackRock Group increased its Jazz Pharmaceuticals (JAZZ) stake by 2.3% in Q4 2016, buying an estimated $1.31M and bringing the position to 521,832 shares worth $56.9M. The position accounts for 0.03% of the portfolio, ranked #571.

BlackRock Group first reported a position in JAZZ in Q2 2013 and has held it in 14 quarters since. The position peaked at $73.2M in Q2 2016. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

BlackRock Group held 521,832 shares of Jazz Pharmaceuticals worth $56.9M as of Q4 2016.
BlackRock Group bought 11,773 Jazz Pharmaceuticals shares in Q4 2016, an estimated $1.31M.
Jazz Pharmaceuticals made up 0.03% of BlackRock Group's portfolio in Q4 2016, its #571 holding.
BlackRock Group first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
BlackRock Group's Jazz Pharmaceuticals position peaked at $73.2M in Q2 2016.
295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.